-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-504358-36-00
5
2024-10-17
multiple sclerosis
-
2022-503112-17-00
5
2024-10-16
Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglyca
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504231-41-01
4
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-505678-14-00
4
2024-08-19
Ulcerative Colitis
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2022-500030-28-01
4
2024-06-10
Urothelial carcinoma
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2022-501599-25-00
5
2024-03-19
juvenile idiopathic arthritis
-
2022-503136-13-00
1
2024-02-29
various B-cell malignancies
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-502783-21-00
5
2024-02-20
B-Cell Non-Hodgkin's Lymphoma
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma
-
2022-503126-12-01
5
2024-01-05
Hypoparathyroidism
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2022-501980-42-00
5
2023-12-21
Anemia associated with Chronic Kidney Disease
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2023-504265-23-00
4
2023-10-23
Crohn's disease
-
2023-504247-13-00
4
2023-10-17
Small Cell Lung Cancer